Global Antimicrobial Resistance Innovation Fund (GAMRIF) - Vaccine Innovation with BactiVac

Vaccine Innovation with BactiVac is a partnership between the UK government and the Bacterial Vaccinology Network (BactiVac) to support the development of vaccines for AMR in humans and animals. The UK government has invested up to £1 million over one year into BactiVac, which is one of 5 networks that are supported by the Global Challenges Research Fund (GCRF) Networks in Vaccines Research & Development. This is co-funded by the Medical Research Council (MRC) and Biotechnology and Biological Sciences Research Council (BBSRC). The primary aim of this investment is to support new, diverse research projects to gain preliminary data and encourage establishment of new research partnerships, and allow these collaborations to build a track record, which will allow them to attain further funding. It is expected that some of these projects will fail, yet the dissemination of both positive and negative research outcomes is valuable and expected. Funded projects will undertake early stage research and development with catalyst pump-priming funding around the world to help drive the development and uptake of vaccines for antimicrobial resistance (AMR) for the benefit of people in low- and middle-income countries (LMICs). Projects funded through the Global AMR Innovation Fund (GAMRIF) will primarily benefit people in LMICs, where the burden of drug-resistant infection is greater.